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Rational Design of Small-Molecule Stabilizers of
Spermine Synthase Dimer by Virtual Screening and Free
Energy-Based Approach
Zhe Zhang1,2,3, Virginie Martiny1,2, David Lagorce1,2, Yoshihiko Ikeguchi4, Emil Alexov3*,
Maria A. Miteva1,2*
1 Université Paris Diderot, Sorbonne Paris Cité, Molécules Thérapeutiques In Silico, Inserm UMR-S 973, Paris, France, 2 INSERM, U973, Paris, France, 3 Computational
Biophysics and Bioinformatics, Department of Physics and Astronomy, Clemson University, Clemson, South Carolina, United States of America, 4 Faculty of Pharmaceutical
Sciences, Josai University, Togane, Japan

Abstract
Snyder-Robinson Syndrome (SRS) is a rare mental retardation disorder which is caused by the malfunctioning of an enzyme,
the spermine synthase (SMS), which functions as a homo-dimer. The malfunctioning of SMS in SRS patients is associated
with several identified missense mutations that occur away from the active site. This investigation deals with a particular
SRS-causing mutation, the G56S mutation, which was shown computationally and experimentally to destabilize the SMS
homo-dimer and thus to abolish SMS enzymatic activity. As a proof-of-concept, we explore the possibility to restore the
enzymatic activity of the malfunctioning SMS mutant G56S by stabilizing the dimer through small molecule binding at the
mutant homo-dimer interface. For this purpose, we designed an in silico protocol that couples virtual screening and a free
binding energy-based approach to identify potential small-molecule binders on the destabilized G56S dimer, with the goal
to stabilize it and thus to increase SMS G56S mutant activity. The protocol resulted in extensive list of plausible stabilizers,
among which we selected and tested 51 compounds experimentally for their capability to increase SMS G56S mutant
enzymatic activity. In silico analysis of the experimentally identified stabilizers suggested five distinctive chemical scaffolds.
This investigation suggests that druggable pockets exist in the vicinity of the mutation sites at protein-protein interfaces
which can be used to alter the disease-causing effects by small molecule binding. The identified chemical scaffolds are druglike and can serve as original starting points for development of lead molecules to further rescue the disease-causing effects
of the Snyder-Robinson syndrome for which no efficient treatment exists up to now.
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rearrangements and the plasticity of protein-protein interfaces
[10,14]. In a more complex case scenario, one could map the
altered PPI into the interactome and consider alternative
approaches to restore the interactome, rather than to focus on a
particular PPI [15,16]. During the last decade, initial research has
been done to use small organic molecules to act as PPIs inhibitors
[17–24] or PPIs stabilizers [7,25–29]. However, efficient modulation of PPI by small drug-like molecules is still considered an
extremely challenging task, which becomes much more difficult
when missense mutations destabilize PPI interactions. In fact, very
few examples of direct or indirect stabilizers of mutation altered
PPIs have been reported [29–32]. For example, in the transthyretin (TTR), several mutations are known to destabilize the TTR
tetramer. The TTR tetramer destabilization facilitates amyloid
fibril formation causing familial amyloid polyneuropathy. A series
of compounds bound to TTR have been found to inhibit the fibril
formation via the stabilization of the TTR tetramer [7,32].
Further, the tumor suppressor p53, a key protein in the cell’s
defense against cancer, is deactivated by mutations in 50% of

Introduction
It is well documented that missense mutations can result in
various human diseases due to their effects on the structure,
function, assemblages, interactions, and other properties of
expressed proteins (see for ex. [1–6]). Some of these changes are
caused by a single mutation in a given protein, other pathologies
can be genetically complex, such as the various cardiovascular
diseases and cancers with several genes contributing to the
disorder [2–4]. Frequently, missense mutations causing such
disorders affect protein-protein interactions (PPIs) or protein
domain interactions [5,7,8]. PPIs are essential component of any
biological system. As over 370,000 PPIs are predicted to take place
within humans [9], the alteration of PPIs is one of the dominant
mechanisms by which missense mutations affect the wild type
functionality. Recent studies demonstrated [8,10–13] that both
disease-causing and harmless missense mutations occurring at the
binding epitope do affect protein interactions. However, the
magnitude of the effect is difficult to predict because of structural
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human cancers [33]. Many of the p53 oncogenic mutants are
deactivated because their stability is lowered so that the protein
denatures very rapidly. Several small molecules stabilizing p53 in a
mutation-specific way (e.g. binding to the mutational cavity of
p53-Y220C) have been identified by using in silico structure-based
screening [30] and fragment-based screening [31].
Discovering druggable pockets and identifying small-molecule
modulators of challenging protein targets, such as PPI [34] or
protein-membrane interactions [35,36], is not an easy biochemical
task. The difficulties can be greatly reduced by utilizing in silico
approaches, in particular in silico screening [37–39]. Even some of
the hit molecules identified in silico do not completely achieve the
desired effect, however, they can serve as templates and can be
further optimized (e.g. refer to the optimization of survivin
dimerization modulators [40]) or can serve as valuable tools for
chemical biology goals [37].
Here, we report a study focusing on a missense mutation G56S
occurring in the vicinity to the homo-dimer interface of the human
enzyme spermine synthase (SMS) and causing a rare mental
retardation disorder, the Snyder Robinson Syndrome (SRS) [41–
44]. The SMS forms a homo-dimer with two identical subunits
and each subunit has two domains: N-terminal domain (NTD) and
C-terminal domain (CTD) (Figure 1). It was shown experimentally
that formation of homo-dimer of SMS is crucial for its enzymatic
activity [45]. The two NTDs from each subunit contain two large
pseudo-symmetric beta sheets forming a dimer interface and
harbor the disease-causing missense mutation G56S. It was shown
that the G56S mutation greatly reduces SMS activity and leads to
severe epilepsy and cognitive impairment [43], along with other
currently known missense mutations [43] p.V132G (c.496 T.G)
[44], p.I150 T (c.550 T.C), and Y328C [46]. The SMS is
involved in the synthesis of polyamines critical for mammalian cell
growth and development [47–50] by converting spermidine (SPD)
into spermine (SPM). The reaction involves an aminopropyl group
to be taken from decarboxylated S-adenosylmethionine (dcAdoMet) and transferred to SPD to form SPM and leaving 59methylthioadenosine (MTA) as a byproduct. The molecular
mechanisms of above mentioned mutations were investigated
[11,12], and specifically we showed, both computationally and
experimentally, that the G56S mutation affects the SMS wild type
function by decreasing homo-dimer stability. [6,12]. Since homodimerization is known to be crucial for the function of SMS, the
disease effect of G56S was attributed to the affected homo-dimer
formation [12].
In our previous work we have exploited the possibility to
increase the SMS activity by stabilizing the homo-dimer of the
SMS mutant G56S through a limited number of small-molecule
stabilizers [51]. Here, we extend our previous investigation and
designed an original in silico protocol-coupling virtual screening
and free binding energy-based approach to identify small-molecule
candidates capable of stabilizing the G56S homo-dimer. In order
to find putative druggable pockets at the mutant dimer interface,
we perform molecular dynamic (MD) simulations of the mutant
homo-dimer structure combined with a Hierarchical Ascendant
Classification (HAC) procedure, which was recently demonstrated
to be highly efficient for the identification of a conformational
ensemble of pockets [52]. The in silico protocol allowed us to
successfully prioritize a very small number of candidates for
in vitro assays starting from more than 2 million chemical
compounds. Among the 51 small molecules experimentally tested,
17 showed an increase of the mutant activity, suggesting that their
binding stabilizes the SMS G56S homo-dimer. Chemical structure
classification allowed to identify five distinct active chemical
scaffolds and the structural origins of the stabilization were
PLOS ONE | www.plosone.org

Figure 1. The 3D structure of human SMS (PDB ID: 3C6K). C
chain is represented in green and D chain is represented in magenta.
The disease-causing mutation G56S is shown in blue spheres; the
substrates SPD (sky blue) and MTA (orange) were shown in stick
representation.
doi:10.1371/journal.pone.0110884.g001

analyzed by combining molecular docking and MD simulations.
The drug-likeness of the identified scaffolds suggests that they may
serve as original starting points for the development of optimized
lead molecules to further rescue the disease-causing effect of
Snyder-Robinson Syndrome.

Results
Overall computational procedure
The following computational procedure was designed to identify
small-molecule stabilizers of the SMS G56S homo-dimer (Figure 2). Details are described in the Methods section. Below we
describe the results of each step separately.

Molecular Dynamics Simulations
We performed molecular dynamic (MD) simulations with 2 ns
production step on both the homo-dimer WT and the homodimer mutant G56S structures. In order to ensure the reliability of
the MD trajectories of the simulated WT/mutant structures, we
calculated the root-mean-square deviations (RMSD) of backbone
atoms for the entire protein against the average MD structure. The

Figure 2. A flowchart of the designed in silico protocol to
identify small-molecule stabilizers of the G56S SMS homodimer.
doi:10.1371/journal.pone.0110884.g002
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average structure (over 2000 snapshots extracted at each 1ps
timestep) was minimized with CHARMM using the same protocol
as for the initial minimization. The RMSD of both the WT and
the mutant homo-dimers are shown in Figure S1. As expected, the
mutant G56S homo-dimer is less stable showing much larger
fluctuations than the WT, as observed in our previous studies
[11,12]. After 500 ps of the production step, the RMSD of the WT
homo-dimer saturated around 1.5 Å, thus, we took the 1500
snapshots from 500 to 2000 ps at each 1ps timestep for the WT
and the mutant for further consideration.
The root-mean-square fluctuations (RMSF) of the Ca atoms are
shown in Figure 3. For comparison, the B-factors of Ca atoms of
the SMS WT X-ray crystal structure are also provided. It can be
seen that the RMSF of the simulated WT structure are in a good
agreement with the B-factors, i.e. the flexible zones observed in the
simulated WT structure are similar to those indicated by the Bfactors in the X-Ray crystal structure. Since the calculated RMSF
closely match the crystallographic B-factors, it can be assumed that
the MD simulation trajectories are reliable and can be used in the
search for putative druggable pockets for virtual screening.
However some differences are noted, e.g. the B-factor of the
residues around Lys 250 is higher in the X-ray crystal structure
than in the fluctuations of the corresponding residues in the
simulated structure. Such differences can be due to the missing
residues in the X-Ray crystal structure, which were rebuilt
in silico. The simulations indicate that the RMSF of the mutant
G56S are relatively higher than those of the WT for the entire
structure as well as in the region around the mutation site. This
observation suggests that the G56S mutation makes SMS homodimer more flexible than the WT SMS.

of transient druggable pockets at the dimer interface in different
conformations that would permit the performing of virtual
screening into alternative cavities and to discover small-molecule
binders with different chemistry. The analysis of the two Nterminal domains (NTD) of both chains in the homo-dimer for
Charmm_mini (Figure 4A) suggests three cavity candidates
(termed subpockets), Pa, Pb, and Pc, which are close to the
mutation site. Subpocket Pa is mostly formed by residues from the
C chain and it is the largest and most hydrophobic one among the
three cavities. Subpocket Pb goes across the dimer interface and is
linked through small channels to both subpockets Pa and Pc.
Subpocket Pc is located at the D chain and contains several
hydrophobic residues (A32, Y62, I78, V84) and two negatively
charged side chains D33 and E35. The minimized average MD
structure Charmm_ave also suggests three subpockets Pa, Pb and
Pc (Figure 4B). Subpockets Pa shows different geometries and
polarities in Charmm_ave and in Charmm_mini. In Charmm_ave, subpocket Pa goes along with the dimer interface towards
the subunit C. The mutation site G56S is located within the deep
cavity of this subpocket. Several polar hot-spot residues are located
in subpocket Pa (H60 from the chain D and N70 form chain C)
creating a strong polar environment. The aromatic Y91 (C chain)
provides a possibility for aromatic/hydrophobic contacts with an
incoming ligand. Subpocket Pc includes the same charged residues
as subpocket Pc in Charmm_mini. In both structures subpocket Pc
is far from the dimer interface. Considering the different polarity
and shape of the subpockets Pa and Pb in Charmm_ave and in
Charmm_mini we retained these zones as putative binding sites
that could accommodate diverse ligands as homo-dimer stabilizers.
In order to find different conformations of the identified
putative binding sites, we employed Hierarchical Ascendant
Classification (HAC) based on the matrix of RMSD for all atoms
of the putative binding pockets of the 1500 MD extracted
snapshots of the mutant homo-dimer. This procedure resulted in 8
homo-dimer conformations with diverse binding pockets. In order
to select the best druggable structure we performed druggability
analysis using the DoGSiteScorer webserver for the obtained 8
centroid homo-dimer conformations (see Table S1). Among the 3
best structures (706ps, 790ps and 1353ps) having pockets close to
the mutation site G56S with druggability score .0.80, we retained
the conformation 706ps, Charmm_706ps, having the druggable
cavity with the biggest volume close to G56S.
In order to analyze the population density of the conformation
706ps we calculated RMSD between the 1500 conformations used
for the HAC analysis and Charmm_706ps (Fig. S2). Only 10
structures were found to be very similar to Charmm_706ps with
RMSD within 1.5 Å. Such result can be expected because the
HAC clustering is done only over the putative binding site residues
in order to find diverse binding site conformations to dock ligands
into. Thus, the obtained centroid structures may not be really
considered as representative for the conformational population of
the entire homo-dimer mutant structure.
Table 1 shows the druggability scores and calculated descriptors
for the best druggable pockets at the entire surface of
Charmm_706ps identified by DoGSiteScorer. The pockets P0
and P4 situated around the homo-dimer interface (see Figure 5)
show high druggability scores of 0.81 and 0.84, respectively. Then,
we used the Surflex protomol tool to analyse the druggability of
Charmm_706ps. We obtained three subpockets Pa, Pb and Pc for
Charmm_706ps (shown in Figure 4C). The subpockets Pa and Pb
have a surface covering the dimer interface larger than in
Charmm_ave, suggesting that small molecules bound in these
subpockets may result in stabilization of the homo-dimer mutant.

Identification and Characterization of Druggable Pockets
at the Homo-Dimer Interface
In order to identify alternative small molecule binding zones at
the homo-dimer interface around the mutation site, we analyzed
the CHARMM minimized mutant structure, Charmm_mini, and
the minimized average mutant structure of the entire MD
production trajectory, Charmm_ave, using protomol probes
generated by Surflex. Such an analysis would allow the discovery

Figure 3. RMSF of simulated WT structure (red) and mutant
G56S structure (black); B factors (Ca atoms) of the WT X-Ray
crystal structure (green). Note that the residue numbers in D chain,
which includes 381 amino acids as C chain, were counted from No. 382
to No. 762. The mutation site G56S in both C chain and D chain is
pointed to by the blue arrow.
doi:10.1371/journal.pone.0110884.g003
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Figure 4. Putative Binding Pockets in the NTD of the Targeted
Mutant Dimer Protein Structures. (A) Charmm_mini; (B) Charmm_ave; (C) Charmm_706ps. In the cartoon representations, the green
and cyan surfaces represent hydrophobic/aromatic residues for chains C
and D, respectively; the red surface represents oxygen atoms; the blue
surface represents nitrogen atoms; the magenta surface represents the
disease-causing missense mutation; the black circles indicate the
subpockets Pa, Pb and Pc.
doi:10.1371/journal.pone.0110884.g004

Table 2 shows all subpockets of Charmm_mini, Charmm_ave and
Charmm_706ps closely placed to the targeted homo-dimer
interface. In fact, the subpocket P4_SP1 (subpocket 1 of pocket
P4) and pocket P21 of Charmm_706ps correspond to the
subpocket Pa shown in Figure 4C. The subpocket P0_SP1 and
pocket P12 of Charmm_706ps correspond to the subpocket Pb
shown in Figure 4C. As seen from Table 2, the highest
druggability score is obtained for the area Pc of Charmm_ave,
yet it is located too far from the dimer interface. Among the three
mutant protein conformations, the best druggability score for a
pocket close to the dimer interface corresponds to the druggable
area Pb of Charmm_706ps. Finally we retained the druggable
areas Pb and Pb of the structures Charmm_706ps, Charmm_mini
and Charmm_ave, which are closely placed to the homo-dimer
interface and show different geometries and polarities for virtual
screening experiments.

Virtual Screening and Free Binding Energy Calculations
In order to identify putative small-molecule stabilizers of the
G56S mutant homo-dimer we performed structure-based virtual
screening of a compound collection of 273,226 diverse drug-like
molecules prepared from more than 2 million chemical compounds. The molecules were docked into the identified putative
binding pockets Pa and Pb of Charmm_706ps, Charmm_mini,
and Charmm_ave structures using Surflex and AutoDock Vina.
The protein conformations were maintained as rigid during the
docking computations. For each protein conformation, an
independent consensus scoring was performed on the top 2000
compounds ranked by Surflex and AutoDock Vina. 214 common
top-ranked compounds were found in all. We found 63 common
molecules with the best scores ranging from 6.8 to 8.75 for Surflex
and from 27.0 to 28.3 for Vina when docking into Charmm_mini. For Charmm_ave, we found 71 common molecules with the
best scores ranging from 7.4 to 9.0 and from 27.7 to 28.6 for
Surflex and Vina, respectively. For Charmm_706ps, we found 80
common molecules with the best scores ranging from 7.1 to 8.6
and from 27.3 to 28.3 for Surflex and Vina, respectively. After an
interactive visual analysis (focused on shape, hydrophobicity, and
polar complementarity) we selected 95 molecules and 2 different
binding modes for each ligand that are the most likely to occur as
predicted by the docking into Charmm_mini, Charmm_ave, and
Charmm_706ps.
To probe the stabilizing effect of the selected 95 ligand candidates,
we decided to compute the binding affinity between the homo-dimer
protein and the small molecules bound at the homo-dimer interface.
Two different protocols based on MD simulations were employed to
compute the binding affinities for the G56S dimer-ligand complex,
DDGbind and DDGbind-relaxed (see Methods for details). We ranked
the 95 ligand candidates by DDGbind and DDGbind-relaxed and the
first 51 best ranked ligands with binding affinity DDGbind or
DDGbind-relaxed better than 220 kcal/mol were selected for experimental validation.
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Table 1. Druggable pockets (P) identified by DoGSiteScorer at the entire surface of Charmm_706ps.

Pocket

Volume [Å3]

Surface [Å2]

Solvent accessible lipophilic
surface [Å2]

Drugability Score

P0

1490.59

1875.12

1296.21

0.81

P1

835.29

1097.69

777.25

0.84

P2

767.53

865.98

523.04

0.84

P3

702.28

812.86

578.89

0.84

P4

536.92

458.24

284.69

0.84

P5

504.30

677.41

364.36

0.79

P6

464.84

605.06

410.05

0.86

P7

411.02

889.07

556.32

0.72

P8

348.84

482.93

347.50

0.69

doi:10.1371/journal.pone.0110884.t001

activity via the homo-dimer stabilization. The measured activity of
G56S SMS in presence of small molecules is shown in Figure 6.
The activity in the presence of the previously tested 10 small
molecules [51] is also given in Figure 6. It is seen that 31 molecules
slightly increase the SMS mutant activity and 7 of them increase

In Vitro Characterization of the Putative G56S SMS
Stabilizers
The selected 51 compounds were purchased and tested
experimentally. The goal of the in vitro experiments was to test
the putative stabilizers for their ability to increase the G56S SMS

Table 2. Druggable pockets (P) and subpockets (SP) identified by DoGSiteScorer close to the targeted dimer interface of
Charmm_mini, Charmm_ave and Charmm_706ps.

Volume

Surface

Solvent accessible
lipophilic surface

Drugability

[Å3]

[Å2]

[Å2]

Score

131.62

394.80

87.07

0.34

140.82

191.20

96.04

0.31

478.78

846.01

509.65

0.53

217.08

454.07

335.51

0.51

146.26

326.75

209.65

0.29

Pa, Pb: P11

221.20

270.06

156.81

0.49

Pc: P8

257.00

516.80

331.28

0.58

Pa: P18

143.59

172.91

103.05

0.30

Pb: P2_SP0

328.41

498.23

344.01

0.40

Pc: P9_SP1

102.88

173.25

100.11

0.37

P9_SP2

87.17

214.45

98.75

0.06

Pocket

Charmm_706ps
Pa: P4_SP1
C chain: R8–R11, S62–F64, Q80–Y82
D chain: W57, R77, Y79, L85
P21
C chain: F36, Q39, M41, N59, S63,
F64, A65, L79, Q80, S81, E91, I92, I95

Pb: P0_SP1
C chain: I120–Y129
D chain: D25, F26, M27, L83–L85,
R122–K124
P12
C chain: L5–G9, D83, V121,
G123–A125
D chain: M27, H81, L83

Pc: P17
D chain: L28, A30, K31, D33, T36,
I37, E114–Q117, S119, T120

Charmm_ave

Charmm_mini

doi:10.1371/journal.pone.0110884.t002
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Binding Affinity Analysis of Mutant Homo-dimer
Stabilizers
An analysis of the predicted binding affinities for all 61
molecules is presented below. The calculated scores of Surflex
and Vina do not show a correlation between the experimentally
found activities and the calculated scores, e.g. the scores do not
distinguish the good (with activity .110%) from the bad (activity
,110%) binders (results not shown). These results can be expected
by taking into account that the reliable prediction of binding
affinities still remains an important challenge in structure-based
virtual screening methodology [53–55]. Current scoring functions
are widely recognized to lack precision in accounting for the
solvation and entropic contribution to ligand binding. Binding free
energy calculations can thus help to prioritize potential binders.
Although we did not find a strong correlation between the
experimental activities and the computed DDGbind or DDGbindrelaxed energies, we should note that the for the best activators
(activity$110%), better binding energies are computed using the
DDGbind-relaxed than using the DDGbind approach (results shown in
Figure S3). These results confirm the importance of considering
the protein flexibility before and after ligand binding in order to
improve the affinity prediction [56]. The binding free energy
calculations allowed for the reduction of twice the number of
compounds selected after docking-scoring (from 95 to only 51) for
the experimental assays.
Figure 7 shows the SMS protein conformations (Charmm_mini,
Charm_ave and Charmm_706ps) which were used to identify
each experimentally validated hit. The previously identified active
molecules (no 1, 2, 3) have been discovered by using docking into
the minimized SMS G56S structure (Charmm_mini). Most of the
molecules identified by docking into Charmm_ave show slight
activity suggesting that the average MD structure (Charmm_ave) is
not the most suitable for putative binder identification. Interestingly, the two newly discovered here most potent compounds (no 4
and 5 with activities 114.4 and 112%, respectively) which contain
2 new scaffolds (see next paragraph) were found by docking into
the snapshot Charmm_706ps which shows the best putative
druggable pocket. This indicates that our procedure of classifying
diverse putative binding sites of G56S SMS homo-dimer using
MD simulations is useful for identifying druggable binding
pockets. In fact, different scaffolds were discovered thanks to
docking into diverse binding site conformations.

Figure 5. Druggable pockets (P) and subpockets (SP) close to
the targeted dimer interface of Charmm_706ps identified by
DoGSiteScorer.
doi:10.1371/journal.pone.0110884.g005

the activity of the G56S SMS by more than 10%. Unexpectedly,
we discovered two molecules that decrease the mutant activity by
15% and 56%, respectively. One may speculate that these
molecules affect the dimer formation or stability since they do
not to contain scaffolds known to inhibit the SMS active site and
are neither reactive nor frequent hitters that might result in false
positive hits (we checked by our software FAFDrugs2, see in
Methods for details).

Figure 6. Activity of small molecules experimentally tested. The
vertical axis of the graph shows activity normalized to 100% for the
G56S SMS mutant without the binding of small molecules. The
horizontal axis indicates the small molecule ID number. The newly
tested here 51 molecules are shown in grey and the previously tested
10 molecules [51] are shown in black.
doi:10.1371/journal.pone.0110884.g006

PLOS ONE | www.plosone.org

Figure 7. Activities (in %) of the 31 hit molecules identified by
docking into the three receptor conformations: Charmm_mini
(in blue bars), Charmm_ave (in red bars), Charmm_706ps (in
green bars). The two newly discovered here most potent compounds
(no 4 and 5) representing 2 new scaffolds are found by docking into the
MD snapshot Charmm_706ps.
doi:10.1371/journal.pone.0110884.g007
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mutant bound to the previously discovered compound 9129729
(shown in Fig. S5) suggest that ligand binding indeed stabilizes the
homo-dimer at the targeted interface. The zone of the residues
Y91-T120 of C chain including Y91, D92, D94 and Q96 and that
around the key residue H60 of D chain, all expected to be key for
the interaction, show reduced fluctuations upon ligand binding.

Structural analysis of the bioactive molecules
In order to identify a diverse chemical series we performed a
chemical similarity search and clustering on 26 bioactive
molecules showing increased activity $105%. The obtained most
active chemical series, which contained at least one molecule with
activity .110%, are shown in Figure 8. The first 3 scaffolds
(clusters I, II, and III) are represented by the ChemBridge
molecules ID: 9129729, 5790328 and 7754012 and have been
identified during a previous virtual screening performed on the
Charmm_mini structure [51]. Two new scaffolds represented by
the molecules ChemDiv ID: E941-0318 and the ChemBridge ID:
5476487 (clusters IV and V) are identified here by docking into the
snapshot structure Charmm_706ps. The physicochemical profiles
of all compounds seen in Figure 8 satisfy the physicochemical
criteria for oral bioavailability. Furthermore, the molecules shown
in Figure 8 do not contain reactive groups, frequent hitters or
PAINS (Pan Assay Interference Compounds) (verified using FAFDrugs2) suggesting that these molecules might be specific binders
for our target.
In order to propose a possible mechanism of action for the
newly discovered scaffold Cluster IV, we re-docked the two
ChemDiv molecules E941-0318 and G796-1817 into the
Charmm_706ps putative binding pockets Pa and Pb. For these
docking experiments, we took the last protein structure of the
G56S dimer of the MD simulation of the complex
Charmm_706ps-E941-0318. The lowest docking energy poses
suggesting similar orientations for E941-0318 and G796-1817
were obtained in the putative binding area Pb (Figure 9) with
docking energies of 27.73 and 27.59 kcal/mol, respectively. In
the putative binding area Pa (Figure S4) the lowest docking
energies were of 27.95 and 26.94 kcal/mol for E941-0318 and
G796-1817, respectively.
The docking experiments shown in Figure 9 suggest that the
end of the propyl side chain, namely the first cycled amine in
E941-0318 and the cycled amine in G796-1817 point toward the
carboxylic group of D94. pKa calculations performed with
MarvinSketch software (ChemAxon 2010) predicted that this
cycled amine is protonated for both E941-0318 and G796-1817.
Thus, the charged cycled amine of E941-0318 and G796-1817
forms a salt bridge with the carboxylic group of D94. In addition
the amide NH of E941-0318 and G796-1817 forms a hydrogen
bond with the carbonyl oxygen of D92. The aromatic cycles of
both molecules are anchored in a deep cavity formed by R17 and
H81, Y79. The docked pose of G796-1817 suggests that its Cl
atom is in contact with H81. Although it is not exactly situated
between the two nitrogen atoms ND1 and NE2, a halogen bond
may be expected because of the short distance between ND1 and
NE2 and the Cl atom. The present data suggests that the small
molecules E941-0318 and G796-1817 fit into the Pb binding
pocket, protrude at the molecular surface, and could indeed
stabilize the protein-protein interactions at the dimer interface and
could thus increase the G56S SMS activity as supported by the
experimental validation. Interestingly, H81, Y79, and Y91 have
also been proposed to be involved in ligand binding for the
previously identified bioactive molecules Chembridge 9129729,
5790328 and 7754012 by docking into the Charmm_mini
conformation. Therefore, the previous and the obtained here
docking results strongly support the potential binding areas Pa and
Pb can be successfully targeted in order to develop small-molecule
stabilizers at the G56S SMS dimer interface.
The stabilization effect due to ligand binding is also supported
by the performed MD simulations of the mutant G56S bound to
identified actives. The RMSF of the mutant G56S, the mutant
bound to the newly identified compound E941-0318, and the
PLOS ONE | www.plosone.org

Discussion
This work focuses on the missense mutation G56S causing
malfunctioning of the enzyme spermine synthase and resulting in
the Snyder-Robinson Syndrome. Our previous computational and
experimental studies [11,12] showed that G56S destabilizes the
SMS homo-dimer without affecting the active site of the enzyme.
Homo-dimer formation is crucial for the normal enzymatic
activity of SMS [45], and thus our goal was to mitigate the effect
of G56S in order to rescue the dimer affinity. Moreover, G56 is
situated in a solvent accessible zone and far from the active site,
thus binding a small molecule around the mutation site would
have a low risk of affecting the active site. This provides an
opportunity to develop an approach aimed at restoring the
enzymatic activity of G56S SMS by stabilizing the G56S mutant
homo-dimer. In vivo, where the SMS molecules are surrounded
by many other molecules in the cell, the small molecule binding
pockets may not be always exposed to the solvent due to transient
interactions with other molecules in the cell. However, these
transient interactions are short-lived, since SMS is known not to
have interacting partners and therefore the small molecules are
expected to be able to reach the pockets without much
obstruction. Much more crucial is the question of unwanted
binding of the small molecules to other off-targets different from
SMS, which often occurs in the cell.
Stabilizers of PPIs can act by variety of potentially complex
mechanisms. For instance, small-molecule binding can be used to
tackle or stabilize transitory complexes [28] or by targeting
allosteric pockets it can also be useful for stabilizing proteins or
PPIs in some cases [57]. Thus, the first challenge that should be
addressed when targeting PPIs by small drug-like molecules is to
identify potentially druggable pockets [34]. It has been recently
shown that protein interaction sites are more predisposed to
surface pocket formation than the rest of the protein surface [58].
This suggests that the more direct way would be to directly target
the PPI interface or domain-domain interface. Some example
cases are the small-molecule stabilizers of the TTR tetramer [32]
or the dimer of human survivin [26,40]. With this, our strategy
was to identify druggable pockets in different conformations at the
homo-dimer interface of G56S SMS. In our previous work [51],
we have targeted the homo-dimer interface close to the mutation
site in a conformation obtained after a molecular mechanics
minimization (Charmm_mini). This resulted in the identification
of the molecules, ChemBridge 9129729, 5790328, and 7754012,
as stabilizers of the G56S SMS homo-dimer. In order to identify
new scaffold molecules, we explored conformational changes that
can occur at the mutant homo-dimer interface through MD which
would permit us to find transitory pockets. Putative druggable
pockets at different modeled conformations were identified in the
vicinity of the mutation site G56S based on the consensus results
for druggability obtained by two different approaches, Surflexprotomol and DoGSiteScorer. The best performing identified
pocket was at the MD snapshot Charmm_706ps, which allowed
the identification of two new stabilizing scaffolds: the molecules
ChemDiv E941-0318 and ChemBridge 5476487. The 5 distinct
scaffolds identified in this work and in our previous one suggest
that druggable pockets exist close to mutation sites at PPIs
7
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Figure 8. Chemical series of the identified bioactive compounds. Radar plots represent the computed oral bioavailability profile (compound
blue line should fall within the optimal green area, white and red ones being extreme zones generally indicating low oral bioavailability). The
computations involved: logP, molecular weight (MW), topological polar surface area (tPSA), rotatable bond (RotBonds), H-bonds acceptors and
donors (HBA, HBD).
doi:10.1371/journal.pone.0110884.g008

interfaces, which can be successfully targeted via small-molecule
binding.
As a proof-of-concept, we combined structure-based virtual
screening and conformational and binding energy analysis via MD
simulations to identify small molecules that increase the activity of
G56S SMS through the mutant homo-dimer stabilization. The
successfully identified molecules that increase the G56S SMS
activity suggest that the employed computational strategy to
explicitly incorporate protein-ligand dynamics into the final
selection of compound candidates has successfully allowed for
the prioritization of the putative homo-dimer interface binders.
Starting from ,2 million in silico-analyzed compounds, we tested
51 compounds experimentally, among them, 23 compounds were
found to slightly increase the G56S SMS activity. Binding free
energy calculations after the MD simulations helped to identify
potential binders. In fact, the best free binding energies for the best
active molecules (increasing the G56S SMS activity by $110%)
were obtained when conformational flexibility of the protein–
ligand complex and of the protein alone were taken into
consideration. There results confirm the gain in virtual screening
accuracy when protein flexibility is incorporated compared to
using scoring functions relying on static conformations of proteinligand complexes, as previously observed [59–63]. This observation must be much more valuable when missense mutations are
present and destabilize proteins or PPIs or domain-domain
interactions. In general, missense mutations increase the conformational space of proteins or their complexes and targeting
druggable pockets in different conformations can be helpful to
identify different scaffold molecules binding at the PPI or dimer
interfaces, as it was demonstrated in this study.
In conclusion, the identified five different scaffolds represent
drug-like molecules without potential reactive or PAINS groups,
which provides a basis for further optimization of these molecules
in order to develop lead therapeutics for Snyder-Robinson
syndrome for which no efficient treatment exists until now. Our
results confirm that the protein conformational analysis and
structure-based virtual screening is a promising approach to target
PPI interfaces with present mutations by drug-like molecules to
modulate PPI for drug discovery and chemical biology projects.

Materials and Methods
I. In silico modeling
Protein Structure. The X-Ray crystal 3D structure of wild
type (WT) human SMS in complex with spermidine (SPD) and 5methylthioadenosine (MTA) (PDB ID: 3C6K) (Figure 1) was
downloaded from the Protein Data Bank (http://www.rcsb.org)
[64]. The crystallographic structure is made of four chains (chains
A, B, C, and D) resulting in two homo-dimers in the asymmetrical
unit cell. As pointed out in our previous work [11,12], the homodimer formed by the A chain and B chain is not suitable for MD
simulations because of significant van der Waals clashes. Due to
this, in this work, we used the dimer formed by the C and D
chains. The missing atoms and residues were rebuilt by ‘‘profix’’, a
module in Jackal package (http://wiki.c2b2.columbia.edu/
honiglab_public/index.php/
Software:Jackal_General_Description). The mutant G56S was
created by the module SCAP [65] in the Jackal package. Figure 1

Figure 9. Lowest docking energy conformations of Cluster IV
bioactive compounds docked with AutoDock into the area Pb
of Charmm_706ps taken after the MD simulation of the
complex Charmm_706ps - E941-0318. The C chain in shown in
green, the D chain is shown in cyan. (A) docked E941-0318 and G7961817 superposed into the Connolly surface of the dimer G56S SMS; (B)
docked E941-0318; (c) docked G796-1817.
doi:10.1371/journal.pone.0110884.g009
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were assembled: Asinex Merged Libraries (436,012 compounds),
ChemBridge Express Pick (324,909 compounds), ChemDiv Full
Discovery Chemistry (1,183,665 compounds), and LifeChemicals
Stocks (344,693 compounds). After removing the redundant
molecules, we employed a drug-like filter using the FAF-Drugs2
web-service [73] previously developed in our lab in order to
remove molecules with undesired physicochemical properties and
reactive groups. It has been recently observed that the physicochemical properties of small molecules acting as protein-protein
interaction (PPI) modulators [24,74–76] differ from those defined
by ‘‘Lipinski’s rule of 5’’ [77]. Such molecules are generally larger
and more lipophilic. In order to increase the chance to find potent
PPI small-molecule stabilizers while remaining drug-like, we
decided to filter our compounds in the ranges: 100, MW
(Molecular Weight) ,700; 0, tPSA (topological polar surface
area),160; 24, logP,6; 0, number of HBD (hydrogen bond
donors) ,5; 0, number of HBA (hydrogen bond acceptors) ,10;
0, Rotatable Bonds ,15. The filtered collection contained
1,960,000 molecules that were clustered using the Cluster
Molecule Protocol (Accelrys Pipeline Pilot v8.5) with the FCFP-4
fingerprint using a maximum distance of Tanimoto of 0.3 in the
clusters. Tanimoto index of 0 means that there are no identical
indices in either molecule and 1 means that both molecules are
composed of identical sets of indices. The 3D structures of the
remaining 273,226 molecules were generated using Corina
program embedded in the Accelrys Pipeline Pilot v8.5. The
procedure was launched keeping a maximum of 2 stereocenters
and a maximum of 4 stereoisomers per compound without
generating multiple ring conformations.
For chemical structural analysis of the identified bioactive
compounds we used two clustering approaches. A first run was
performed with the Cluster Molecule Protocol (Accelrys Pipeline
Pilot v8.5) and the MDL keys. A Tanimoto similarity index of 0.6
was used to assess the similarity between all pair of compounds
and 11 clusters were obtained. A second clustering procedure was
carried out with Stardrop (http://www.optibrium.com/) in order
to define a final chemical series. It creates chemical space
projections based on a combination of chemical structure and
properties.
Virtual Screening and Docking. Docking of the prepared
273,226 compounds from Asinex, ChemBridge, ChemDiv and
LifeChemicals was performed into different protein binding pocket
conformations using two software packages, Surflex [71] and
AutoDock Vina [78]. Surflex creates a protomol of chemical
probes to which potential ligands are aligned by incremental
construction based on the molecular similarity. In this work, we
generated Surflex protomol based on the selected residues in the
binding pockets. The residue lists are provided in Table S4. In
addition, the parameter ‘‘proto_thresh’’ was set to control the
degree of burying (Table S5 of supporting information) and the
parameter ‘‘proto_bloat’’ was set to indicate how far the protomol
should be expanded (Table S5). During the docking process, the
docking accuracy parameter (-pgeom) was used to start each
docking run from 5 different initial poses to ensure good search
coverage. We performed several post-processing runs to optimize
the scoring parameters. The ‘‘polar’’ term was increased to 1.5;
while the ‘‘penetration’’ term, was set to ‘‘23.0’’ (default value).
This term ‘‘23.0’’ allows some protein-ligand atom overlaps,
thereby permitting a slight ‘‘induced fit’’.
AutoDock Vina employs a gradient-based conformational
search approach and defines the search space by a grid box
defined by the box center coordinates and its dimensions of x, y
and z. We used grid resolution of 1 Å, number of binding modes of
10, and exhaustiveness of 8. The other parameters set used for

shows the WT 3D structure and the mutation site G56. In this
paper, we kept the original residue number 56 according to
previously published papers [43,45] for the mutation site G56
(G71 in FASTA sequence) while the other residue numbers
mentioned in this paper correspond to the protein sequence in
FASTA file. The protonation states of the titratable groups were
calculated with Multi Conformation Continuum Electrostatics
(MCCE, version 2.4) [66–68]. The dielectric constant for MCCE
was 8.0. The results of pKa calculation suggested that several His
(Table S2) are neutral and the hydrogen atoms of these His (Hd or
He) were placed according to the obtained pKa values.
Molecular Dynamics Simulations. MD simulations were
performed for the WT and the mutant homo-dimer structures
using CHARMM program (Chemistry at HARvard Macromolecular Mechanics, version c35b1) [69]. The substrates (SPD and
MTA) in SMS complex were removed for the simulations since
they are situated at the C-terminal domain (CTD) far from the
mutation site G56S located at the N-terminal domain. The
solvation was taken into account by the Generalized Born implicit
solvent function FACTS [70]. The WT and the mutant homodimer structures were initially minimized using 500 steps of a
steepest descent algorithm followed by 500 steps of a conjugate
gradient algorithm. Distances between heavy atoms and hydrogen
atoms were constrained by the SHAKE algorithm allowing for a
time step of 2 fs. The system was heated during 100 ps to reach
300 K and then equilibrated during 200 ps with a temperature
window of 300610 K. The production time was 2 ns for each MD
simulation run. Based on the MD analysis, we found that the long
NTD tail of 9 amino acids of the mutant dimer is extremely
flexible and might cover the binding pocket in some MD
snapshots. Therefore we removed 9 residues of the MD snapshot
Charmm_706ps (M1-H9) for further docking and binding free
energy calculations.
Identification of Putative Binding Pockets. We performed
interactive structural analysis of the minimized and the averaged
MD trajectory mutant homo-dimer structures using a probemapping algorithm of Surflex-Protomol [71] (with CH4, C = O,
and N-H groups as probes) to identify the zones capable of binding
small-molecule ligands. In order to generate alternative conformations of the identified putative binging sites, we extracted 1500
snapshots at each 1ps timestep from the last 1500 ps of the MD
trajectory of the mutant homo-dimer structure of SMS. Root
Mean Square Deviations (RMSD) between the 1500 structures
were calculated over all atoms of the putative binding sites (Table
S3). We clustered the different conformations of the binding sites
by applying the Hierarchical Ascendant Classification (HAC) on
the obtained RMSD matrix using the aggregative method Ward as
implemented in R (http://cran.r-project.org/) and a RMSD
distance of at least 1.3Å. We took the centroid structure of the 8
obtained clusters in order to define a representative set of binding
site conformations for further analysis.
We used the probe-mapping algorithm of Surflex-Protomol and
the webserver DoGSiteScorer (http://dogsite.zbh.uni-hamburg.
de/), to characterize the selected mutant dimer conformations
[72]. DoGSiteScorer automatically detects druggable pockets by
employing a support vector machine method and performing
several pocket descriptor calculations. It returns a score of pocket
druggability between 0 and 1 (0– non-druggable, 1– druggable).
We applied DoGSiteScorer on the entire dimer structure to
predict the druggable pockets and to compute pocket descriptors
including volume, surface, lipophilicity, and druggability score.
Chemical Compound Collection. To provide valuable
starting points for the virtual and in vitro screens, we prepared a
diverse chemical compound collection. Four commercial libraries
PLOS ONE | www.plosone.org
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running AutoDock Vina are provided in Table S6. The protein
was prepared with the graphical user interface AutoDockTools
(ADT) [79]. The grid enveloped the entire binding pocket surface
of the targeted protein structures. The scoring of the generated
docking poses and ranking of the ligands was based on the Vina
empirical scoring function approximating the binding affinity in
kcal/mol.
Additional docking experiments were executed with AutoDock4
[79] for further analysis of the binding modes of bioactive
compounds, taking into account local receptor flexibility. We
carried out docking in the binding zones Pa and Pb of the
Charmm_706ps structure taken after the MD simulation of the
complex Charmm_706ps - E941-0318 using a grid containing
446806100 grid points with a spacing of 0.375 Å. All torsions of the
ligands and the side chains of the R17 (C chain) and H81 (D chain)
were allowed to rotate. The Lamarckian genetic algorithm (LGA)
was used to generate orientations/conformations of the compound.
Thirty docking runs were performed, with an initial population of
150 random individuals and a maximum number of 256106 energy
evaluations. The two mostly populated lowest energy positions were
obtained for subpockets Pa and Pb.
Free Binding Energy-Based approach. The binding energy calculations were performed with CHARMM. The topology/
parameter files for small molecules were created by the webserver
Swissparam (http://swissparam.ch) [80]. For each complex
containing the SMS dimer and a bound small molecule, we ran
MD simulation with production step of 2 ns and then we
calculated the average of the energies obtained for the last 20
complex structures taken from the last 20 ps. We used 2 protocols,
noted as ‘‘rigid’’ (Eq.1) and ‘‘relaxed’’ (Eq.2) ones, to calculate the
free binding energy DDGbind between the protein dimer and a
small molecule:

II. Experimental validation
Production of G56S SMS mutant. A DNA fragment
encoding human SMS was amplified by PCR and subcloned into
the pQE-30 vector downstream of the polyhistidine coding region
[81]. The resulting plasmids were used to transform XL1-Blue
cells. Recombinant human SMS was purified by immobilized
metal affinity chromatography using the TALON affinity resin
(Clontech Laboratories, Palo Alto, CA, U.S.A.), in accordance
with the manufacturer’s instruction. The G56S mutated SMS was
generated by PCR and subcloned into the pQE-30 vector. The
entire coding sequence of the G56S SMS mutants was verified by
DNA sequencing to ensure that no other mutations were
introduced during PCR. The entire coding region of plasmids
was verified by DNA sequencing carried out by the Macromolecular Core Facility, Hershey Medical Center.
In vitro assay of G56S SMS activity. The activity of G56S
SMS mutants was measured in absence and in presence of small
molecules. Details on the SMS activity measurements can be
obtained from existing literature [82]. The small molecule
candidates selected from the in silico analysis were dissolved in
5% BSA solution and the experiments were done with small
molecules at 100 uM. The G56S mutant protein itself had little
activity compared with WT (1.3% of WT activity) [51]. However,
the addition of 5% BSA increased G56S mutant activity by
122.2% (a 2.22-fold increase in activity) [51]. Activity was
measured by following the production of spermine from spermidine in 100 mM sodium phosphate buffer (pH 7.5) in the presence
of 0.1 mM dcAdoMet as the propylamine donor. Reactions were
run for 60 min and polyamines were extracted in 10% trichloroacetic acid. The extracts were directly injected onto the ophthalaldehyde postcolumn ion-exchange HPLC system [83]. The
activity measurements were performed two times and no
differences were found.

DDGbind ~DG ðcomplexÞ{DGðprotein dimerÞ{DG ðligand Þ ð1Þ

Supporting Information

where DDGbind is the free binding energy between the protein
dimer and the ligand; DG(complex) is the potential energy of the
complex; DG(protein dimer) is the potential energy of the protein
dimer extracted from the complex; and DG(ligand) is the potential
energy of the ligand extracted from the complex. The DDGbindrelaxed is computed using eq.2:
DDGbind{relaxed ~
DGðcomplexÞ{DGr ðprotein dimerÞ{DGr ðligand Þ

Figure S1 RMSD for backbone atoms between the MD
trajectory and the minimized average structure (Red:
WT; Black: Mutant G56S). The production time was set to
2000 steps and each timestep is 1ps.
(TIFF)
Figure S2 RMSD for backbone atoms between the 1500
conformations used for the HAC analysis and
Charmm_706ps.
(TIFF)

ð2Þ

where DDGbind-relaxed is the free binding energy between the
protein dimer and the small molecule calculated by the relaxed
approach; DG(complex) is the potential energy of the complex;
DGr(protein dimer) is the potential energy of the protein dimer
calculated from MD simulations performed on the protein dimer
alone; and DGr(ligand) is the potential energy of the ligand
calculated from MD simulations performed on the small molecule
alone. The difference between (1) and (2) is that the energies in
Eq.2 are calculated from 3 independent MD simulation runs for
the complex, the protein dimer, and the ligand. The (1) and (2)
were used to estimate the effect of small molecule binding on the
stability of the dimer through the ligand binding energy taking into
consideration that only the dimer interface zone was targeted by
the ligands. The potential energy components include molecular
mechanics energy, electrostatic interactions, and solvation energy.
Entropic effects are implicitly taken into account in (2) because the
MD simulation of the protein-ligand pair and the protein and
ligands alone permits to account for entropy and dynamics [63].
PLOS ONE | www.plosone.org

Figure S3 Experimental activities (in %, the horizontal
axis) and computed DDGbind (in red rectangles) and
DDGbind-relaxed (in blue diamonds) energies (in kcal/mol,
the vertical axis).
(TIFF)
Figure S4 Lowest docking energy conformations of
Cluster IV bioactive compounds docked with AutoDock
into the area Pa of Charmm_706ps taken after the MD
simulation of the complex Charmm_706ps - E941-0318.
The C chain in shown in green, the D chain is shown in cyan. (A)
docked E941-0318 and G796-1817 superposed into the Connolly
surface of the dimer G56S SMS; (B) docked E941-0318; (C)
docked G796-1817.
(TIFF)
Figure S5 RMSF during MD simulations of mutant
G56S (black), mutant G56S bound to the compound
9129729 (red) and mutant G56S bound to the compound
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E941-0318 (green). Note that the residue numbers in D chain,
which includes 381 amino acids as C chain, were counted from
No. 382 to No. 762. The mutation site G56S in both C chain and
D chain is pointed to by the blue arrow.
(TIFF)

Table S5 Parameters to control the degree of burying
(proto_thresh) and extention (proto_bloat) of the protomol.
(DOCX)
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dimension of the grid box used for docking with
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